Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bausch + Lomb Corporation Common Shares (NY:BLCO)

16.69 -0.34 (-2.00%)
Streaming Delayed Price Updated: 12:03 PM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bausch + Lomb Corporation Common Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Bausch + Lomb Announces New Scientific Data and Analyses Featuring Consumer, Vision Care and Pharmaceutical Products Will Be Presented During American Optometric Association's Optometry's Meeting
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Launches Biotrue® Hydration Boost Contact Lens Rehydrating Drops in the United States
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Launches Bausch + Lomb INFUSE® Multifocal Silicone Hydrogel Contact Lenses in the United States
From Bausch + Lomb Corporation
Via Business Wire
News headline image
9 Analysts Have This to Say About Bausch & Lomb ↗
 
Via Benzinga
News headline image
Looking Into Bausch & Lomb's Return On Capital Employed ↗
 
Via Benzinga
News headline image
Bausch & Lomb's Return On Capital Employed Insights ↗
 
Via Benzinga
News headline image
Bausch + Lomb Announces Key Leadership Changes
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb and Novaliq Announce FDA Approval of MIEBO™ (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Inflationary Factors And Slow Product Uptake Could Be Headwinds For Bausch + Lomb, Analyst Says ↗
 
Via Benzinga
News headline image
Recap: Bausch & Lomb Q1 Earnings ↗
 
Via Benzinga
News headline image
Analyst Expectations for Bausch & Lomb's Future ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Bausch & Lomb ↗
 
Via Benzinga
News headline image
Bausch + Lomb Announces First-Quarter 2023 Results and Provides 2023 Guidance
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Releases Annual Environmental, Social and Governance Report
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Announces the Presentation of New Scientific Data on Products and Pipeline Programs at the American Society of Cataract and Refractive Surgery Annual Meeting
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Announces 2023 Annual Meeting of Shareholder Results
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Announces U.S. Launch of StableVisc™ Cohesive Ophthalmic Viscosurgical Device and TotalVisc™ Viscoelastic System
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Announces the Presentation of New Data on Products and Pipeline Programs at the Association for Research in Vision and Ophthalmology Meeting
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Reports More Than 65 Million Units of Contact Lens, Eye Care and Lens Care Materials Recycled Through ONE by ONE and Biotrue® Eye Care Recycling Programs
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Will Release First-Quarter 2023 Financial Results on May 3
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb and Heidelberg Engineering Announce the Introduction of SeeLuma™ Fully Digital Surgical Visualization Platform
From Bausch + Lomb
Via Business Wire
News headline image
Bausch + Lomb Appoints Bob Bailey as Executive Vice President and Chief Legal Officer and Andrew Stewart as President, Ophthalmic Pharmaceuticals
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb and Novaliq Announce Publication of Second Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in American Journal of Ophthalmology
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2023 ↗
 
Via Benzinga
News headline image
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2022 Results
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Trade Desk, Roblox, Herbalife And Other Big Stocks Moving Higher On Wednesday ↗
U.S. stocks traded lower, with the Dow Jones dropping over 150 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Bausch + Lomb Appoints Brent Saunders as Chief Executive Officer and Chair of the Board of Directors, Effective March 6, 2023
From Bausch + Lomb Corporation
Via Business Wire
News headline image
New Bausch + Lomb Social Media Campaign Highlights What ‘Sights’ Inspire AMD Patients
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb and Modulight Announce FDA Approval of ML6710i Photodynamic Laser for Use with Bausch + Lomb’s VISUDYNE® (Verteporfin for Injection)
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2022 Financial Results on February 22
From Bausch + Lomb Corporation
Via Business Wire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.